Contact Us
800.227.0627

Cancer - TEW

 
Print Print
Please select subject area:
Cancer
Biosyn
Therapeutic tiny or short modified antisense oligonucleotides (Tiny ASOs) can block gene expression or modulate splice-switching!
11/06/2023
Biosyn
Therapeutic Antisense Oligonucleotides (ASOs) and their Modifications
10/25/2023
Biosyn
Recent methods for the analysis of miRNA pathways
10/11/2023
Biosyn
The antimicrobial wasp Polybia-MP1 peptide selectively kills bacterial cells!
10/02/2023
Biosyn
Reducing off-target effects of the siRNA therapeutics via placing a morpholino group at the 5’-end of the passenger strand
08/29/2023
Biosyn
The efficacy of FDA-approved drug inhibiting the ‘cap snatching’ endonuclease of RdRP polymerase is undermined by the emergence of resistant influenza virus strains
04/06/2023
Biosyn
MITO-Porters Enable Delivery of Antisense Drugs to Mitochondria
02/27/2023
Biosyn
Antisense Oligonucleotides as Tracers for PET Imaging
01/31/2023
Biosyn
Affinity-controlled release of 5-fluorouracil by synthetic peptide D-Leu-Phe-Phe-derived hydrogels for the potential treatment of skin cancer
01/27/2023
Biosyn
Kaposi’s sarcoma in immunosuppressed patients due to chemotherapy or transplantation, FDA-approved peptide drug to curb HIV-1 infection, and potential peptide drugs to block COVID-19 infection
12/13/2022
Biosyn
Targeting the amino acid tyrosine of peptides or antibodies for selective bioconjugation of therapeutics
10/27/2022
Biosyn
Writers, Readers, and Erasers of RNA Modifications
09/19/2022
Biosyn
The RNA TrimethylGuanosine or TMG cap
09/08/2022
Biosyn
Development of a therapeutic peptidomimetic inhibiting main protease to reduce the level of RdRP polymerase that replicates COVID-19 coronavirus genome
08/16/2022
Biosyn
Exploring the efficacy of combination therapy for DNA crosslinking drug mitomycin C (or antimetabolite drug 5-fluorouracil) and the synthetic strategies for crosslinked oligonucleotide duplex
06/14/2022
1234567
imgscroll